	RW cohort (N=493)	Trial eligible–like cohort[a] (n=162)	IMpower133 study population (N=201)[b]
Follow-up, median, mo	6.9	7.6	13.9
Tx duration, median (95% CI), mo	5.7 (5.1, 6.7)	6.2 (5.5, 7.8)	4.7 (range, 0-21)[c]
rwPFS, median (95% CI), mo	5.2 (5.0, 5.5)	5.8 (5.2, 6.7)	5.2 (4.4, 5.6)[d]
Sensitivity analysis[e]	n=137	n=51	
Follow-up, median, mo[e]	14.4	14.1	
Tx duration, median (95% CI), mo[e]	4.8 (4.1, 5.5)	5.5 (4.8, 7.1)	
rwPFS, median (95% CI), mo[d]	4.8 (4.1, 5.4)	5.8 (4.7, 7.9)	

[a] A subgroup of RW pts comprising IMpower133 eligible pts.
[b] Horn L, et al. *NEJM* 2018.
[c] Not based on Kaplan-Meier methodology.
[d] PFS was measured as a primary endpoint in IMpower133.
[e] Includes only pts initiating tx at least 12 mo before study end.

Clinical Trial Registration

NCT02763579